Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial

Laura Galli, Vincenzo Spagnuolo, Alba Bigoloni, Antonella D. Monforte, F. Montella, Andrea Antinori, A. Di Biagio, S. Rusconi, Giovanni Guaraldi, Simona Di Giambenedetto, M. Borderi, Davide Gibellini, Giada Caramatti, Adriano Lazzarin, Antonella Castagna, Claudio Viscoli, Antonio Di Biagio, Andrea Parisini, Roberta Prinapori, F. MazzottaS. Lo Caputo, Massimo Di Pietro, C. Tincati, T. Bini, E. Merlini, M. Puoti, M. C. Moioli, M. Montella, F. Di Sora, A. Antinori, Adriana Ammassari, Sandrine Valerie Ottou, R. Cauda, S. Di Giambenedetto, Massimo Galli, Stefano Rusconi, Marco Franzetti, G. Rizzardini, Amedeo F. Capetti, A. Castagna, Vincenzo Spagnuolo, Silvia Nozza, Nicola Gianotti, Paola Cinque, Simonetta Gerevini, F. Ferretti, A. Lazzarin, L. Galli, Elisabetta Carini, Alb Bigoloni, C. Vinci, A. Galli, S. Salpietro, Andrea Poli, Cristina Mussini, Giovanni Guaraldi

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To report the 96 week results on efficacy, safety and bone mineral density (BMD) in subjects with HIV-1 that were virologically suppressed and treated with atazanavir/ritonavir monotherapy versus atazanavir/ ritonavir triple therapy. Methods: MODAt is a prospective, multicentre, open-label, non-inferiority, randomized, 96 week trial (NCT01511809) comparing efficacy of atazanavir/ritonavir monotherapy versus atazanavir/ritonavir triple therapy. Treatment success was defined as no occurrence of confirmed viral rebound (two consecutive HIV-RNA >50 copies/mL) or discontinuation for any cause of the ongoing regimen. Results: The 96 week treatment success was 64% in the atazanavir/ritonavir monotherapy arm and 63% in the triple-therapy arm (difference 1.3%, 95% CI: 217.5 to 20.1). In the atazanavir/ritonavir monotherapy arm, no PI- or NRTI-associated resistance mutations were observed at virological failure and all patients re-suppressed after re-intensification. In the monotherapy arm, treatment failure was more frequent in patients coinfected with hepatitis C virus [64%versus 28%(difference 35.4%, 95%CI: 3.7-67.2)]. Drug-related adverse events leading to discontinuation were 3 (6%) in the atazanavir/ritonavir monotherapy arm and 11 (21.5%) in the triple-therapy arm(P=0.041). The 96 week adjusted mean percentage change in total proximal femur (not at lumbar spine) BMD was +1.16% and 21.64% in the atazanavir/ritonavir monotherapy arm and the triple-therapy arm, respectively (P=0.012). Conclusions: The 96 week analyses suggested that long-term efficacy of atazanavir/ritonavir monotherapy was inferior as compared with atazanavir/ritonavir triple therapy, particularly when administered in subjects coinfected with hepatitis C virus. In the atazanavir/ritonavir monotherapy arm, reintroduction of nucleosides, as needed, was always effective with no new resistance mutation; monotherapy was also associated with a lower incidence of adverse events and improvement in femur BMD.

Original languageEnglish
Pages (from-to)1637-1642
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume71
Issue number6
DOIs
Publication statusPublished - Jun 13 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial'. Together they form a unique fingerprint.

Cite this